Compare VANI & SRFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VANI | SRFM |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.0M | 117.5M |
| IPO Year | 2014 | 2023 |
| Metric | VANI | SRFM |
|---|---|---|
| Price | $1.20 | $0.90 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $3.50 | $3.25 |
| AVG Volume (30 Days) | 151.4K | ★ 3.7M |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.69 |
| EPS | ★ N/A | N/A |
| Revenue | $4,000,000.00 | ★ $106,557,000.00 |
| Revenue This Year | N/A | $25.90 |
| Revenue Next Year | N/A | $20.72 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $0.84 |
| 52 Week High | $1.92 | $9.35 |
| Indicator | VANI | SRFM |
|---|---|---|
| Relative Strength Index (RSI) | 48.87 | 35.68 |
| Support Level | $1.13 | N/A |
| Resistance Level | $1.25 | $1.20 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 50.00 | 19.37 |
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
Surf Air Mobility Inc is a regional air mobility platform operating commuter airlines in the United States and expanding an on-demand charter marketplace for passengers in the U.S. and globally. It is also focused on developing a proprietary aviation software, aircraft electrification powertrain technology and services to enable electrification across the regional air mobility sector. The company operates in a single reportable segment, Air Mobility. The Air Mobility segment derives revenue from operating scheduled commercial air service flights, which are sold to the public mainly on a per-seat basis; through subsidized EAS revenue awards from the Department of Transportation; and by operating on-demand flights for customers on an ad-hoc, by request basis.